Drugs / BITR2101
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06385522 | Aug 2025 → Jun 2026 overdue | primary cutaneous T-cell lymphoma | Boston Immune Technologies and Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BITR2101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06385522 ↗ |
| Modality | Monoclonal antibody | “TNFR2 monoclonal antibody” NCT06385522 ↗ |
| Route | Intravenous | “All patients will receive BITR2101 by a 3 hour infusion into a vein” NCT06385522 ↗ |